Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Oric Pharmaceuticals says ORIC-101 safety data shows Phase 2 dose well tolerated » 16:58
06/02/21
06/02
16:58
06/02/21
16:58
ORIC

Oric Pharmaceuticals

$21.29 /

-1.65 (-7.19%)

The company states:…

The company states: "ORIC Pharmaceuticals announced initial data from an ongoing Phase 1b study evaluating ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel, in advanced solid tumors. The data will also be presented in two posters at ASCO Annual Meeting to be held June 4 - 8, 2021. The Phase 1b clinical trial of ORIC-101 in combination with nab-paclitaxel is a single arm, multicenter, open-label study conducted in two parts, intended to establish the recommended Phase 2 dose, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity when administered to patients with advanced or metastatic solid tumors... The efficacy evaluable population included a total of 23 patients who had an opportunity for at least one on-treatment tumor assessment. Five partial responses were observed, one confirmed and four unconfirmed, including in heavily pretreated patients with PDAC, endometrial and breast cancers, who previously progressed on or after a taxane-based therapy. Further evidence of antitumor activity was demonstrated by prolonged disease stabilization across multiple solid tumors, including PDAC, breast, gastric, esophageal, and testicular cancers. Notably, three of the four efficacy evaluable patients with late-line relapsed PDAC treated at the RP2D demonstrated extended progression free survival ranging from 3.6 months to 5.3+ months in the third-line or later setting, despite having already previously progressed on nab-paclitaxel."

ShowHide Related Items >><<
ORIC Oric Pharmaceuticals
$21.29 /

-1.65 (-7.19%)

ORIC Oric Pharmaceuticals
$21.29 /

-1.65 (-7.19%)

03/25/21 H.C. Wainwright
Oric Pharmaceuticals price target raised to $54 from $52 at H.C. Wainwright
01/25/21 Citi
Oric Pharmaceuticals downgraded to Neutral from Buy at Citi
08/13/20
Fly Intel: Top five analyst initiations
08/13/20 Baird
Baird starts Oric Pharmaceuticals at Outperform with $45 price target
ORIC Oric Pharmaceuticals
$21.29 /

-1.65 (-7.19%)

  • 13
    Nov
ORIC Oric Pharmaceuticals
$21.29 /

-1.65 (-7.19%)

Conference/Events
Oric Pharmaceuticals participates in a conference call with JPMorgan » 09:42
05/25/21
05/25
09:42
05/25/21
09:42
ORIC

Oric Pharmaceuticals

$22.72 /

+ (+0.00%)

Conference call with CEO…

Conference call with CEO Chacko will be held on May 25 at 11 am hosted by JPMorgan.

ShowHide Related Items >><<
ORIC Oric Pharmaceuticals
$22.72 /

+ (+0.00%)

ORIC Oric Pharmaceuticals
$22.72 /

+ (+0.00%)

03/25/21 H.C. Wainwright
Oric Pharmaceuticals price target raised to $54 from $52 at H.C. Wainwright
01/25/21 Citi
Oric Pharmaceuticals downgraded to Neutral from Buy at Citi
08/13/20
Fly Intel: Top five analyst initiations
08/13/20 Baird
Baird starts Oric Pharmaceuticals at Outperform with $45 price target
ORIC Oric Pharmaceuticals
$22.72 /

+ (+0.00%)

  • 13
    Nov
ORIC Oric Pharmaceuticals
$22.72 /

+ (+0.00%)

Hot Stocks
Oric Pharmaceuticals to host KOL call to review data on ORIC-101 » 08:04
05/25/21
05/25
08:04
05/25/21
08:04
ORIC

Oric Pharmaceuticals

$22.72 /

-2.285 (-9.14%)

ORIC Pharmaceuticals…

ORIC Pharmaceuticals announced that the company will host a conference call and webcast to review initial data from the ongoing Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in advanced solid tumors. On the conference call, management will be joined by trial investigator and senior author, Professor Pamela Munster, M.D., Director of the Early Phase Clinical Trials Unit and Co-Leader of the Center for BRCA Research at the University of California San Francisco. The data will also be presented in two posters at the American Society of Clinical Oncology Annual Meeting to be held June 4 - 8, 2021.

ShowHide Related Items >><<
ORIC Oric Pharmaceuticals
$22.72 /

-2.285 (-9.14%)

03/25/21 H.C. Wainwright
Oric Pharmaceuticals price target raised to $54 from $52 at H.C. Wainwright
01/25/21 Citi
Oric Pharmaceuticals downgraded to Neutral from Buy at Citi
08/13/20
Fly Intel: Top five analyst initiations
08/13/20 Baird
Baird starts Oric Pharmaceuticals at Outperform with $45 price target
ORIC Oric Pharmaceuticals
$22.72 /

-2.285 (-9.14%)

  • 13
    Nov
ORIC Oric Pharmaceuticals
$22.72 /

-2.285 (-9.14%)

Conference/Events
Oric Pharmaceuticals management to meet virtually with Oppenheimer » 04:55
05/24/21
05/24
04:55
05/24/21
04:55
ORIC

Oric Pharmaceuticals

$24.93 /

-0.19 (-0.76%)

Virtual Meeting to be…

Virtual Meeting to be held on May 24 hosted by Oppenheimer.

ShowHide Related Items >><<
ORIC Oric Pharmaceuticals
$24.93 /

-0.19 (-0.76%)

03/25/21 H.C. Wainwright
Oric Pharmaceuticals price target raised to $54 from $52 at H.C. Wainwright
01/25/21 Citi
Oric Pharmaceuticals downgraded to Neutral from Buy at Citi
08/13/20
Fly Intel: Top five analyst initiations
08/13/20 Baird
Baird starts Oric Pharmaceuticals at Outperform with $45 price target
ORIC Oric Pharmaceuticals
$24.93 /

-0.19 (-0.76%)

  • 13
    Nov
ORIC Oric Pharmaceuticals
$24.93 /

-0.19 (-0.76%)

Over a month ago
Conference/Events
Oric Pharmaceuticals management to meet virtually with Oppenheimer » 10:49
05/21/21
05/21
10:49
05/21/21
10:49
ORIC

Oric Pharmaceuticals

$24.73 /

-0.39 (-1.55%)

Virtual Meeting to be…

Virtual Meeting to be held on May 24 hosted by Oppenheimer.

ShowHide Related Items >><<
ORIC Oric Pharmaceuticals
$24.73 /

-0.39 (-1.55%)

03/25/21 H.C. Wainwright
Oric Pharmaceuticals price target raised to $54 from $52 at H.C. Wainwright
01/25/21 Citi
Oric Pharmaceuticals downgraded to Neutral from Buy at Citi
08/13/20
Fly Intel: Top five analyst initiations
08/13/20 Baird
Baird starts Oric Pharmaceuticals at Outperform with $45 price target
ORIC Oric Pharmaceuticals
$24.73 /

-0.39 (-1.55%)

  • 13
    Nov
ORIC Oric Pharmaceuticals
$24.73 /

-0.39 (-1.55%)

Conference/Events
Oric Pharmaceuticals management to meet virtually with Oppenheimer » 04:55
05/17/21
05/17
04:55
05/17/21
04:55
ORIC

Oric Pharmaceuticals

$25.34 /

+1.23 (+5.10%)

Virtual Meeting to be…

Virtual Meeting to be held on May 17 hosted by Oppnheimer.

ShowHide Related Items >><<
ORIC Oric Pharmaceuticals
$25.34 /

+1.23 (+5.10%)

03/25/21 H.C. Wainwright
Oric Pharmaceuticals price target raised to $54 from $52 at H.C. Wainwright
01/25/21 Citi
Oric Pharmaceuticals downgraded to Neutral from Buy at Citi
08/13/20
Fly Intel: Top five analyst initiations
08/13/20 Baird
Baird starts Oric Pharmaceuticals at Outperform with $45 price target
ORIC Oric Pharmaceuticals
$25.34 /

+1.23 (+5.10%)

  • 13
    Nov
ORIC Oric Pharmaceuticals
$25.34 /

+1.23 (+5.10%)

Conference/Events
Oric Pharmaceuticals management to meet virtually with Oppenheimer » 10:56
05/14/21
05/14
10:56
05/14/21
10:56
ORIC

Oric Pharmaceuticals

$25.05 /

+0.935 (+3.88%)

Virtual Meeting to be…

Virtual Meeting to be held on May 17 hosted by Oppnheimer.

ShowHide Related Items >><<
ORIC Oric Pharmaceuticals
$25.05 /

+0.935 (+3.88%)

03/25/21 H.C. Wainwright
Oric Pharmaceuticals price target raised to $54 from $52 at H.C. Wainwright
01/25/21 Citi
Oric Pharmaceuticals downgraded to Neutral from Buy at Citi
08/13/20
Fly Intel: Top five analyst initiations
08/13/20 Baird
Baird starts Oric Pharmaceuticals at Outperform with $45 price target
ORIC Oric Pharmaceuticals
$25.05 /

+0.935 (+3.88%)

  • 13
    Nov
ORIC Oric Pharmaceuticals
$25.05 /

+0.935 (+3.88%)

Syndicate
Oric Pharmaceuticals files automatic mixed securities shelf  16:36
05/06/21
05/06
16:36
05/06/21
16:36
ORIC

Oric Pharmaceuticals

$23.82 /

+0.25 (+1.06%)

 
ShowHide Related Items >><<
ORIC Oric Pharmaceuticals
$23.82 /

+0.25 (+1.06%)

03/25/21 H.C. Wainwright
Oric Pharmaceuticals price target raised to $54 from $52 at H.C. Wainwright
01/25/21 Citi
Oric Pharmaceuticals downgraded to Neutral from Buy at Citi
08/13/20
Fly Intel: Top five analyst initiations
08/13/20 Baird
Baird starts Oric Pharmaceuticals at Outperform with $45 price target
ORIC Oric Pharmaceuticals
$23.82 /

+0.25 (+1.06%)

  • 13
    Nov
ORIC Oric Pharmaceuticals
$23.82 /

+0.25 (+1.06%)

Recommendations
Oric Pharmaceuticals price target raised to $54 from $52 at H.C. Wainwright » 06:05
03/25/21
03/25
06:05
03/25/21
06:05
ORIC

Oric Pharmaceuticals

$24.25 /

+0.15 (+0.62%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Robert Burns raised the firm's price target on Oric Pharmaceuticals to $54 from $52 and reiterates a Buy rating on the shares following the company's 2020 report. Oric ended 2020 with $293.6M in cash, cash equivalents and marketable securities, which should be sufficient to provide an operational runway into the second half of 2023, Burns tells investors in a research note.

ShowHide Related Items >><<
ORIC Oric Pharmaceuticals
$24.25 /

+0.15 (+0.62%)

ORIC Oric Pharmaceuticals
$24.25 /

+0.15 (+0.62%)

01/25/21 Citi
Oric Pharmaceuticals downgraded to Neutral from Buy at Citi
08/13/20
Fly Intel: Top five analyst initiations
08/13/20 Baird
Baird starts Oric Pharmaceuticals at Outperform with $45 price target
08/12/20 Baird
Oric Pharmaceuticals initiated with an Outperform at Baird
ORIC Oric Pharmaceuticals
$24.25 /

+0.15 (+0.62%)

  • 13
    Nov
  • 24
    Apr
ORIC Oric Pharmaceuticals
$24.25 /

+0.15 (+0.62%)

Earnings
Oric Pharmaceuticals reports Q4 EPS (84c), consensus (46c) » 16:10
03/23/21
03/23
16:10
03/23/21
16:10
ORIC

Oric Pharmaceuticals

$24.05 /

-1.6 (-6.24%)

Reports research and…

Reports research and development expenses were $12.1M for the three months ended December 31, 2020, compared to $7.0 million for the three months ended December 31, 2019. Cash, cash equivalents and short-term investments totaled $293.6M as of December 31, 2020, which included gross proceeds of $133.3M from the follow-on financing completed in November 2020. The company expects its current cash, cash equivalents and short-term investments will be sufficient to fund its current operating plan into the second half of 2023. Jacob Chacko, M.D., president and CEO, said, "The progress we made in 2020 has positioned us for a dynamic 2021, with our first data from two ongoing trials of our lead program ORIC-101 and three IND/CTAs for our other product candidates, a significant amount of development activity for a company at our stage."

ShowHide Related Items >><<
ORIC Oric Pharmaceuticals
$24.05 /

-1.6 (-6.24%)

ORIC Oric Pharmaceuticals
$24.05 /

-1.6 (-6.24%)

01/25/21 Citi
Oric Pharmaceuticals downgraded to Neutral from Buy at Citi
08/13/20
Fly Intel: Top five analyst initiations
08/13/20 Baird
Baird starts Oric Pharmaceuticals at Outperform with $45 price target
08/12/20 Baird
Oric Pharmaceuticals initiated with an Outperform at Baird
ORIC Oric Pharmaceuticals
$24.05 /

-1.6 (-6.24%)

  • 13
    Nov
  • 24
    Apr
ORIC Oric Pharmaceuticals
$24.05 /

-1.6 (-6.24%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.